Fig. (5) (A) Course of treatment of Case 5. The ordinate indicates the dose of 5-ALA (left) and the concentration of CRP (right). The abscissa indicates the date. The initial dose of 5-ALA was 750 mg/day and it was increased to 1500 mg/day on April 12 because the combined camostat was stopped. On April 14 CRP and clinical symptoms much improved and the dose of 5-ALA was reduced on April 15. It was further reduced on April 16. (B) Chest CT scan of case 5 taken on April 10. Ground-glass opacities in the left lobe area are observed in this slice. (C) Chest CT scan taken on May 7. Pulmonary lesions were almost completely improved.